Intech Investment Management LLC purchased a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH – Free Report) in the third quarter, HoldingsChannel reports. The institutional investor purchased 15,079 shares of the company’s stock, valued at approximately $874,000.
Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC bought a new position in Astrana Health during the third quarter worth $34,000. Nisa Investment Advisors LLC acquired a new stake in Astrana Health in the 3rd quarter worth $35,000. KBC Group NV bought a new position in shares of Astrana Health during the 3rd quarter worth about $70,000. Quest Partners LLC acquired a new position in shares of Astrana Health during the third quarter valued at about $133,000. Finally, Central Pacific Bank Trust Division acquired a new position in shares of Astrana Health during the third quarter valued at about $160,000. 52.77% of the stock is owned by institutional investors.
Astrana Health Trading Up 0.9 %
Shares of Astrana Health stock opened at $42.86 on Friday. The stock has a market capitalization of $2.41 billion, a P/E ratio of 32.97, a price-to-earnings-growth ratio of 1.97 and a beta of 1.24. Astrana Health, Inc. has a 12-month low of $32.32 and a 12-month high of $63.20. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The company has a 50-day simple moving average of $53.37 and a 200 day simple moving average of $47.95.
Analyst Upgrades and Downgrades
Several research firms have commented on ASTH. TD Cowen started coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 price target for the company. BTIG Research raised their target price on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. KeyCorp initiated coverage on shares of Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Stifel Nicolaus raised their price objective on shares of Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, Truist Financial lifted their target price on shares of Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $65.17.
View Our Latest Stock Analysis on ASTH
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Featured Articles
- Five stocks we like better than Astrana Health
- Investing In Preferred Stock vs. Common Stock
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- How to Buy Cheap Stocks Step by Step
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Stock Market Sectors: What Are They and How Many Are There?
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH – Free Report).
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.